In This Section
Dr. Lin studies RNA modifications (a.k.a "epitranscriptomics") in human diseases, including cancer. She develops and applies high-throughput sequencing strategies and transcriptome engineering technologies to study the regulation and function of RNA modifications, including A-to-I RNA editing and m6A RNA methylation.
Dr. Lin studies post-transcriptional RNA processing and modifications that are important mechanisms for gene regulation and functional diversity in eukaryotic cells. RNA editing has emerged as an important and widespread mechanism for generating transcriptome diversity in eukaryotic cells. Aberrant RNA editing has been implicated in a variety of diseases including neurological diseases and cancer.
The most abundant type of RNA editing is the A-to-I RNA editing (the deamination of adenosine to inosine) mediated by the ADAR family of RNA editing enzymes. Dr. Lin and her lab team combine genomic, bioinformatic, and molecular approaches to study the regulation, genetic variation, and function of A-to-I RNA editing, as well as the roles of RNA editing in shaping complex traits and diseases.
N6-methyladenosine (m6A) is an abundant and dynamically regulated class of RNA base modification in mRNAs and non-coding RNAs. It affects multiple aspects of RNA metabolism and controls developmental transitions by regulating mRNA decay and translation.
Dr. Lin is developing sensitive sequencing methods to detect RNA m6A methylation in a wider array of clinical and biological samples and using transcriptome engineering technologies to investigate the regulatory and functional consequences of m6A methylation.
Education and Training
BS, Peking University (Biotechnology), 2001
PhD, University of California, Los Angeles (Cellular and Molecular Pathology), 2007
Fellowship, University of Iowa (Internal Medicine), 2011
Titles and Academic Titles
Assistant Professor of Pathology and Laboratory Medicine
Postdoctoral Travel Award, American Society for Biochemistry and Molecular Biology, 2009, 2010